Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Quisovalimab - Avalo Therapeutics

Next Previous
Drug Profile

Quisovalimab - Avalo Therapeutics

Alternative Names: AEVI-002; Anti-CD258 monoclonal antibody; Anti-LIGHT monoclonal antibody; Anti-TNFSF14-monoclonal-antibody; AVTX-002; CERC 002; MDGN-002; SAR 252067

Latest Information Update: 02 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kyowa Hakko Kirin; La Jolla Institute for Allergy & Immunology
  • Developer Avalo Therapeutics; Kyowa Hakko Kirin; Sanofi; The Childrens Hospital of Philadelphia
  • Class Anti-inflammatories; Antiasthmatics; Antivirals; Monoclonal antibodies
  • Mechanism of Action Tumour necrosis factor ligand superfamily member 14 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Asthma; COVID-19 pneumonia; Crohn's disease; Inflammatory bowel diseases; SARS-CoV-2 acute respiratory disease
  • No development reported Ulcerative colitis

Most Recent Events

  • 28 Oct 2024 No recent reports of development identified for clinical-Phase-Unknown development in Ulcerative-colitis in USA (SC)
  • 28 Jan 2024 No recent reports of development identified for phase-I development in Crohn's-disease(Treatment-experienced, In adults) in USA (SC)
  • 26 Jun 2023 Adverse events and efficacy data from a phase II PEAK trial in Asthma released by Avalo Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top